Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.860 EUR | -0.34% |
|
+1.03% | -10.40% |
Jun. 04 | Hyloris Partner Avenacy's Intravenous Tranexamic Acid Application Gets US FDA Nod | MT |
May. 22 | Hyloris Pharmaceuticals Lands Exclusive Commercialization Deal for Xtraza Oral Rinse | MT |
Capitalization | 164M 189M 155M 140M 260M 16.38B 293M 1.83B 700M 7.51B 710M 695M 27.59B | P/E ratio 2025 * |
-7.92x | P/E ratio 2026 * | -11.1x |
---|---|---|---|---|---|
Enterprise value | 171M 198M 161M 147M 271M 17.11B 306M 1.91B 732M 7.84B 741M 726M 28.82B | EV / Sales 2025 * |
21.7x | EV / Sales 2026 * | 5x |
Free-Float |
43.38% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
More press releases
More news
1 day | -0.34% | ||
1 week | +1.03% | ||
Current month | -0.68% | ||
1 month | +3.17% | ||
3 months | -13.06% | ||
6 months | +10.57% | ||
Current year | -10.40% |
1 week | 5.54 | ![]() | 5.92 |
1 month | 5.54 | ![]() | 6.3 |
Current year | 4.42 | ![]() | 7.2 |
1 year | 2.89 | ![]() | 11.7 |
3 years | 2.89 | ![]() | 15.16 |
5 years | 2.89 | ![]() | 19.1 |
10 years | 2.89 | ![]() | 19.1 |
Manager | Title | Age | Since |
---|---|---|---|
Thomas Jacobsen
CEO | Chief Executive Officer | 51 | - |
Stijn van Rompay
CEO | Chief Executive Officer | 49 | 2011-12-31 |
Director of Finance/CFO | - | 2024-12-08 |
Director | Title | Age | Since |
---|---|---|---|
Stijn van Rompay
BRD | Director/Board Member | 49 | 2020-11-29 |
Thomas Jacobsen
BRD | Director/Board Member | 51 | 2011-12-31 |
Stefan Yee
CHM | Chairman | 63 | 2019-09-30 |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-0.34% | +1.03% | -49.91% | -59.59% | 189M | ||
-2.84% | -6.91% | -13.71% | +156.52% | 685B | ||
-0.62% | -4.65% | +0.70% | -13.42% | 360B | ||
-0.10% | -3.02% | +8.75% | +29.16% | 327B | ||
-2.58% | -7.83% | -51.84% | +25.00% | 326B | ||
-0.27% | -3.86% | +2.57% | -13.95% | 255B | ||
-0.34% | -2.34% | +0.96% | +20.36% | 228B | ||
-1.52% | -5.41% | -16.68% | +2.61% | 217B | ||
-0.29% | -3.24% | -39.52% | -10.19% | 199B | ||
-0.10% | -2.00% | -6.11% | +21.36% | 156B | ||
Average | -0.90% | -3.65% | -16.48% | +15.78% | 275.22B | |
Weighted average by Cap. | -1.31% | -4.71% | -12.62% | +44.68% |
2025 * | 2026 * | |
---|---|---|
Net sales | 7.9M 9.11M 7.44M 6.76M 12.51M 789M 14.09M 88.12M 33.72M 361M 34.17M 33.45M 1.33B | 33.3M 38.39M 31.37M 28.5M 52.73M 3.32B 59.41M 371M 142M 1.52B 144M 141M 5.6B |
Net income | -23.4M -26.98M -22.04M -20.03M -37.05M -2.34B -41.75M -261M -99.89M -1.07B -101M -99.07M -3.93B | -18.95M -21.85M -17.85M -16.22M -30.01M -1.89B -33.81M -211M -80.89M -867M -81.98M -80.23M -3.19B |
Net Debt | 7.3M 8.42M 6.88M 6.25M 11.56M 729M 13.02M 81.43M 31.16M 334M 31.58M 30.91M 1.23B | 2.5M 2.88M 2.35M 2.14M 3.96M 250M 4.46M 27.89M 10.67M 114M 10.81M 10.58M 420M |
More financial data
* Estimated data
Employees
49
Sector
Pharmaceuticals
Calendar
Sep. 24
- Q2 2025 Earnings Release
Date | Price | Change | Volume |
---|---|---|---|
25-06-20 | 5.860 € | -0.34% | 2,771 |
25-06-19 | 5.880 € | +0.34% | 2,119 |
25-06-18 | 5.860 € | -0.68% | 12,413 |
25-06-17 | 5.900 € | 0.00% | 763 |
25-06-16 | 5.900 € | +1.72% | 3,650 |
Real-time Euronext Bruxelles, June 20, 2025 at 11:35 am EDT
More quotesSell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
5.860EUR
Average target price
12.50EUR
Spread / Average Target
+113.31%
Annual profits - Rate of surprise
- Stock Market
- Equities
- HYL Stock
Select your edition
All financial news and data tailored to specific country editions